Psoriatic arthritis has a strong hereditary component, but it is not inherited in a simple, predictable pattern. About 40% of people with the condition have at least one close family member who also has psoriasis or psoriatic arthritis. If your parent or sibling has psoriatic arthritis, your risk is roughly 30 times higher than someone with no family history, making genetics one of the most significant risk factors. Still, genes alone don’t determine whether you’ll develop it.
Family Risk Is Substantial
The most direct evidence for a hereditary link comes from studying families. In a study of 100 people with psoriatic arthritis and their 289 first-degree relatives (parents, siblings, and children), 7.6% of those relatives also had the condition. Among siblings specifically, the rate was 7.7%. That may sound modest, but psoriatic arthritis affects roughly 0.25% of the general population. The gap between those two numbers, expressed as a “recurrence risk ratio,” is about 30. For context, a ratio of 30 means you’re 30 times more likely to develop psoriatic arthritis if a sibling has it than if no one in your family does. That’s an unusually high familial clustering for a non-Mendelian disease.
Psoriasis itself also runs in these families. About 15 to 18% of first-degree relatives of people with psoriatic arthritis had psoriasis, even without joint involvement. So inheriting susceptibility to psoriasis and inheriting susceptibility to joint disease overlap significantly, though they’re not identical.
It’s Polygenic, Not Simple Inheritance
Psoriatic arthritis doesn’t follow a straightforward dominant or recessive inheritance pattern. You can’t trace it through a family tree the way you might with a condition like sickle cell disease. Instead, it’s classified as a complex polygenic trait, meaning many genes each contribute a small amount of risk, and those genes interact with environmental factors to determine whether the disease actually develops.
Researchers have now identified over 100 distinct genetic regions linked to psoriasis susceptibility. A large 2025 meta-analysis pooling data from 18 genome-wide association studies found 109 loci associated with the disease, including 46 to 50 that hadn’t been previously identified in European populations. Many of these overlap with psoriatic arthritis risk. The genes involved tend to affect immune system function, particularly pathways involving inflammatory signaling molecules like IL-17, which plays a central role in the joint and skin inflammation characteristic of the disease.
Specific immune system gene variants show up more often in people with psoriatic arthritis. The HLA-B*57 variant, for example, was found in about 24% of patients in one study compared to just 7.5% of healthy controls. HLA-C*06, another immune-related variant, appeared in 29% of patients versus 16% of controls. These variants influence how your immune system identifies threats, and carrying them raises your risk, but plenty of people carry these variants and never develop the condition.
Twin Studies Complicate the Picture
Twin studies are the classic tool for separating genetic from environmental influence. If a disease were purely genetic, identical twins (who share 100% of their DNA) would almost always both develop it. For psoriatic arthritis, the data is surprising: in one study, only 1 out of 10 identical twin pairs were both affected, and 1 out of 26 fraternal twin pairs were both affected. The nearly identical concordance rates between the two groups suggest that while genes create vulnerability, something beyond DNA is needed to trigger the disease. The researchers themselves emphasized the importance of continuing to search for non-genetic factors in psoriatic arthritis.
This stands in contrast to psoriasis alone, where identical twins show much higher concordance. It suggests that the “arthritis” part of psoriatic arthritis may depend more heavily on environmental triggers than the skin component does.
Environmental Triggers That Activate Genetic Risk
Having the genetic susceptibility is like having a loaded gun. Environmental factors pull the trigger. Several are well established.
Physical trauma is one of the more striking examples. In people who already have psoriasis, injuries like fractures, contusions, or even surgical incisions can trigger joint inflammation through what’s called the deep Köbner phenomenon. The injury doesn’t damage the joint directly in a way that causes arthritis. Instead, it sets off an inflammatory cascade: tissue damage sends inflammatory signals like TNF-alpha and IL-17 into nearby joint tissue, causing the synovium (the lining of the joint) to become inflamed. Nerve endings activated by the injury also release chemicals that promote swelling, tissue breakdown, and abnormal bone growth at the sites where tendons attach to bone.
This mechanism helps explain a curious pattern: even routine mechanical stress matters. People with psoriatic arthritis often show thickening of structures under regular physical load, like the tendon pulleys in the fingers. Daily activities and exercise, while generally healthy, can initiate or worsen inflammation at these stress points in genetically susceptible individuals.
Beyond trauma, obesity, infections, and psychological stress are all linked to higher rates of psoriatic arthritis. Psoriasis itself is connected to cardiovascular disease, diabetes, and depression, and these overlapping conditions create a web of inflammation that can push susceptible joints over the threshold into active disease.
Can Genetic Testing Predict Your Risk?
No genetic test currently available can tell you whether you’ll develop psoriatic arthritis. The condition involves too many genes, each with a small effect, for any single test to be meaningfully predictive. Early research into risk prediction models that combine genetic markers has shown promising results in identifying which psoriasis patients are most likely to progress to joint disease, but these models haven’t yet been validated widely enough for clinical use.
The practical value of genetic research right now lies more in treatment than prediction. The 2025 genome-wide studies identified variants in genes that encode known drug targets, including the receptor for IL-17 (already targeted by existing medications) and newly identified genes like STAP2 and POU2F3 that could lead to future therapies. For people already diagnosed, understanding the genetic pathways driving their disease is gradually leading to more precisely targeted treatments.
What This Means for Your Family
If you have psoriatic arthritis, your children and siblings are at meaningfully elevated risk compared to the general population, but “elevated risk” is not the same as certainty. The 7.6% prevalence among first-degree relatives means that more than 9 out of 10 close family members will not develop the condition. The most practical step for relatives is awareness: knowing that persistent joint pain, stiffness, swollen fingers or toes, or nail changes in someone with a family history of psoriasis or psoriatic arthritis warrant early evaluation. Early treatment significantly improves long-term joint outcomes, and the window for intervention is more useful than any genetic test currently available.